Syneos Health Stock

Syneos Health FCF Conversion

Delisted·Sep 29, 2023

The FCF Conversion Rate (FCF/EBITDA) of Syneos Health (SYNH) as of Aug 13, 2026 is 125.15 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 167.54 % — a change of -25.30% (lower).

FCF Conversion

125.15 %

YoY

-25.30%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Syneos Health is 2026 125.15 % . FCF Conversion Rate (FCF/EBITDA) of Syneos Health was 2025 167.54 % . It decreases by -25.30% lower compared to the previous year.
Access this data via the Eulerpool API

Syneos Health Stock analysis

What does Syneos Health do? Syneos Health is a US-based pharmaceutical and biotech service company. They specialize in providing integrated solutions for clinical research, commercial services, and data analysis. The company was founded in 2017 through the merger of two leading service companies, INC Research and inVentiv Health. Today, Syneos Health is one of the largest providers of clinical and commercial services in the pharmaceutical and biotech industry. They support their customers in the development and marketing of medications, diagnostics, and medical devices by offering a wide range of services including planning and conducting clinical trials, data analysis and management, and product marketing. Syneos Health operates in four business areas: clinical solutions, commercial solutions, consulting services, and clinical data analysis. Their primary focus is on delivering customer-centric services that cover various aspects of the pharmaceutical and biotech industry value chain. Within their clinical and medical segment, they conduct clinical trials and provide supporting services. They have expertise in clinical research and have successfully executed numerous studies. Syneos Health also offers consulting services in the areas of data management systems and clinical trials. In the commercial segment, they assist customers with marketing, sales promotion, and channel management to ensure the successful launch and sales of products. They provide training for sales staff, market research and analysis, and continuous support from sales and marketing experts. Their consulting services encompass strategy consulting, market research, branding, and communication. They also assist with the development, implementation, and validation of clinical trials, literature research, and regulatory support. Syneos Health's clinical data analysis involves analyzing large data sets to gain insights into the healthcare industry. They utilize cutting-edge technologies such as Big Data Analytics and Machine Learning to provide customers with valuable insights that aid in decision-making. In addition to clinical trials and consulting, Syneos Health offers modern technologies for the development and marketing of medications. This includes Virtual Reality solutions, personalized patient programs for chronic disease treatment, and digital platforms for data collection, analysis, and management. Syneos Health serves globally operating pharmaceutical and biotech companies that rely on their services to develop and market innovative medications and treatment methods. Customers value Syneos Health's expertise and trust that the company will help them successfully bring their products to market. Overall, Syneos Health is a leading company in the pharmaceutical and biotech industry. Their integrated services enable customers to work faster and more effectively. By combining expertise in clinical research, commercial solutions, consulting services, and clinical data analysis, Syneos Health offers innovative and successful solutions to its customers. Syneos Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Syneos Health stock

FCF Conversion Rate (FCF/EBITDA) of Syneos Health is 125.15 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Syneos Health changed from 167.54 % to 125.15 %, representing a -25.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Syneos Health since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Syneos Health with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Syneos Health

All Key Metrics — Syneos Health